Cargando…
Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer
INTRODUCTION: D-CARE, an international, phase 3, randomized, double-blind, placebo-controlled study in women with early-stage breast cancer at high risk of disease recurrence, failed to meet its primary endpoint—improvement in bone metastasis-free survival (BMFS) with adjuvant denosumab vs placebo i...
Autores principales: | Coleman, Robert, Zhou, Ying, Jandial, Danielle, Cadieux, Benoit, Chan, Arlene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342342/ https://www.ncbi.nlm.nih.gov/pubmed/34185259 http://dx.doi.org/10.1007/s12325-021-01812-9 |
Ejemplares similares
-
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
por: Palmerini, Emanuela, et al.
Publicado: (2021) -
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
por: Cadieux, Benoit, et al.
Publicado: (2022) -
Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023) -
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis
por: Huang, Shang-Yi, et al.
Publicado: (2020) -
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
por: Sakaguchi, Koichi, et al.
Publicado: (2019)